Publications

BibTex format

@article{His:2019:10.1186/s12916-019-1408-4,
author = {His, M and Viallon, V and Dossus, L and Gicquiau, A and Achaintre, D and Scalbert, A and Ferrari, P and Romieu, I and Onland-Moret, NC and Weiderpass, E and Dahm, CC and Overvad, K and Olsen, A and Tjønneland, A and Fournier, A and Rothwell, JA and Severi, G and Kühn, T and Fortner, RT and Boeing, H and Trichopoulou, A and Karakatsani, A and Martimianaki, G and Masala, G and Sieri, S and Tumino, R and Vineis, P and Panico, S and van, Gils CH and Nøst, TH and Sandanger, TM and Skeie, G and Quirós, JR and Agudo, A and Sánchez, M-J and Amiano, P and Huerta, JM and Ardanaz, E and Schmidt, JA and Travis, RC and Riboli, E and Tsilidis, KK and Christakoudi, S and Gunter, MJ and Rinaldi, S},
doi = {10.1186/s12916-019-1408-4},
journal = {BMC Medicine},
pages = {1--13},
title = {Prospective analysis of circulating metabolites and breast cancer in EPIC},
url = {http://dx.doi.org/10.1186/s12916-019-1408-4},
volume = {17},
year = {2019}
}

Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - BackgroundMetabolomics is a promising molecular tool to identify novel etiologic pathways leading to cancer. Using a targeted approach, we prospectively investigated the associations between metabolite concentrations in plasma and breast cancer risk.MethodsA nested case-control study was established within the European Prospective Investigation into Cancer cohort, which included 1624 first primary incident invasive breast cancer cases (with known estrogen and progesterone receptor and HER2 status) and 1624 matched controls. Metabolites (n = 127, acylcarnitines, amino acids, biogenic amines, glycerophospholipids, hexose, sphingolipids) were measured by mass spectrometry in pre-diagnostic plasma samples and tested for associations with breast cancer incidence using multivariable conditional logistic regression.ResultsAmong women not using hormones at baseline (n = 2248), and after control for multiple tests, concentrations of arginine (odds ratio [OR] per SD = 0.79, 95% confidence interval [CI] = 0.70–0.90), asparagine (OR = 0.83 (0.74–0.92)), and phosphatidylcholines (PCs) ae C36:3 (OR = 0.83 (0.76–0.90)), aa C36:3 (OR = 0.84 (0.77–0.93)), ae C34:2 (OR = 0.85 (0.78–0.94)), ae C36:2 (OR = 0.85 (0.78–0.88)), and ae C38:2 (OR = 0.84 (0.76–0.93)) were inversely associated with breast cancer risk, while the acylcarnitine C2 (OR = 1.23 (1.11–1.35)) was positively associated with disease risk. In the overall population, C2 (OR = 1.15 (1.06–1.24)) and PC ae C36:3 (OR = 0.88 (0.82–0.95)) were associated with risk of breast cancer, and these relationships did not differ by breast cancer subtype, age at diagnosis, fasting status, menopausal status, or adiposity.ConclusionsThese findings point to potentially novel pathways and biomarkers of
AU  - His,M
AU  - Viallon,V
AU  - Dossus,L
AU  - Gicquiau,A
AU  - Achaintre,D
AU  - Scalbert,A
AU  - Ferrari,P
AU  - Romieu,I
AU  - Onland-Moret,NC
AU  - Weiderpass,E
AU  - Dahm,CC
AU  - Overvad,K
AU  - Olsen,A
AU  - Tjønneland,A
AU  - Fournier,A
AU  - Rothwell,JA
AU  - Severi,G
AU  - Kühn,T
AU  - Fortner,RT
AU  - Boeing,H
AU  - Trichopoulou,A
AU  - Karakatsani,A
AU  - Martimianaki,G
AU  - Masala,G
AU  - Sieri,S
AU  - Tumino,R
AU  - Vineis,P
AU  - Panico,S
AU  - van,Gils CH
AU  - Nøst,TH
AU  - Sandanger,TM
AU  - Skeie,G
AU  - Quirós,JR
AU  - Agudo,A
AU  - Sánchez,M-J
AU  - Amiano,P
AU  - Huerta,JM
AU  - Ardanaz,E
AU  - Schmidt,JA
AU  - Travis,RC
AU  - Riboli,E
AU  - Tsilidis,KK
AU  - Christakoudi,S
AU  - Gunter,MJ
AU  - Rinaldi,S
DO  - 10.1186/s12916-019-1408-4
EP  - 13
PY  - 2019///
SN  - 1741-7015
SP  - 1
TI  - Prospective analysis of circulating metabolites and breast cancer in EPIC
T2  - BMC Medicine
UR  - http://dx.doi.org/10.1186/s12916-019-1408-4
UR  - https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-019-1408-4
UR  - http://hdl.handle.net/10044/1/73676
VL  - 17
ER  -

Download

ProfessorElioRiboli

Contact

Assistant

Location

Summary

Citation

BibTex format

RIS format (EndNote, RefMan)